1-4 of 4
Douglas Bootle
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PD5-5: Phase I study of the PI3Kα inhibitor BYL719 plus fulvestrant in patients with PIK3CA-altered and wild type ER+/HER2- locally advanced or metastatic breast cancer

Filip Janku, Dejan Juric, Javier Cortes, Hope Rugo, Howard A Burris, Martin Schuler, Barbara Deschler-Baier, Mark R Middleton, Marta Gil-Martin, Jordan Berlin, Eric Winer, Douglas Bootle, Lars Blumenstein, David Demanse, Christina Coughlin, Cornelia Quadt, José Baselga
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): PD5-5.
https://doi.org/10.1158/1538-7445.SABCS14-PD5-5
Published: 01 May 2015
View article titled, Abstract PD5-5: Phase I study of the PI3Kα inhibitor BYL719 plus fulvestrant in patients with <em>PIK3CA</em>-altered and wild type ER+/HER2- locally advanced or metastatic breast cancer
Journal Articles

Abstract LB-65: Towards defining the genetic framework for clinical response to treatment with BYL719, a PI3Kalpha-specific inhibitor.

Jordi Rodon, Dejan Juric, Ana-Maria Gonzalez-Angulo, Johanna Bendell, Jordan Berlin, Douglas Bootle, Kathlene Gravelin, Alan Huang, Adnan Derti, Joseph Lehar, Jens Würthner, Markus Boehm, Eliezer van Allen, Nikhil Wagle, Levi A. Garraway, Roman Yelensky, Philip J. Stephens, Vincent A. Miller, Robert Schlegel, Cornelia Quadt, José Baselga
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): LB-65.
https://doi.org/10.1158/1538-7445.AM2013-LB-65
Published: 15 April 2013
View article titled, Abstract LB-65: Towards defining the genetic framework for clinical response to treatment with BYL719, a PI3Kalpha-specific inhibitor.
Journal Articles

Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study

Dejan Juric, Jordi Rodon, Ana M. Gonzalez-Angulo, Howard A. Burris, Johanna Bendell, Jordan D. Berlin, Mark R. Middleton, Douglas Bootle, Markus Boehm, Antonin Schmitt, Nicolas Rouyrre, Cornelia Quadt, Jose Baselga
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): CT-01.
https://doi.org/10.1158/1538-7445.AM2012-CT-01
Published: 15 April 2012
View article titled, Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study
Journal Articles

In Vitro and in Vivo Reversal of P-Glycoprotein-mediated Multidrug Resistance by a Novel Potent Modulator, XR9576

Prakash Mistry, Alistair J. Stewart, Wendy Dangerfield, Sade Okiji, Chris Liddle, Douglas Bootle, Jane A. Plumb, David Templeton, Peter Charlton
Journal: Cancer Research
Cancer Res (2001) 61 (2): 749–758.
Published: 01 January 2001
View article titled, <em>In Vitro and in Vivo</em> Reversal of P-Glycoprotein-mediated Multidrug Resistance by a Novel Potent Modulator, XR9576
Open the PDF for <em>In Vitro and in Vivo</em> Reversal of P-Glycoprotein-mediated Multidrug Resistance by a Novel Potent Modulator, XR9576 in another window